HHS: Adding Inflation-Based Rebates to Medicare Part B Could Top $1.8 Billion in Savings

Drug Industry Daily
If Congress were to require a Medicaid-style rebate structure for Medicare Part B prescription drugs, drugmakers would have to pay at least $1.8 billion in annual rebates — about 9 percent of Medicare’s total spending on pharmaceuticals in 2015 — according to an HHS analysis.

To View This Article:


Subscribe To Drug Industry Daily